報價延遲最少15分鐘:2025/01/21 08:37 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.16 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.34/-0.73
|
|
企業價值
20.44M
|
| 資產負債 |
|
每股賬面淨值
-0.02
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
18.00K
|
|
每股收益
0.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 08:37 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BioSig Technologies Inc is a commercial-stage medical device company with an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), It is committed to addressing healthcare's biggest priorities saving time, saving costs, and saving lives. Its first product, the PURE EP System, is an FDA-cleared non-invasive class II device consisting of a unique combination of hardware and software designed to provide unprecedented signal clarity and precision for real-time visualization of intracardiac signals paving the way for personalized patient care. |